The target-disease model that shaped modern pharma is increasingly breaking down. Advances in molecular biology reveal a fragmented, redundant, and combinatorial biological reality, with major implications for clinical trials, costs, and market access.
In this talk, Prof. Dr. Matthias P. Schönermark explores where artificial intelligence truly creates value in today’s biopharma landscape and where its limits remain. While AI can accelerate existing paradigms by improving target validation, responder prediction, and combination strategies, it cannot yet generate new biological frameworks.
The event brings together professionals working at the intersection of AI, life sciences, and healthcare, followed by informal discussion, drinks, and networking.
Time
6:30 – 9:30 PM
• 6:30 PM Doors open
• 7:00 PM Talk
• 8:00 PM Networking & drinks
Participation
Free of charge, registration required
Approval required
Hosted by
idalab Seminar
In collaboration with
Bundesverband der Pharmazeutischen Industrie e.V.
idalab office
Potsdamer Straße 68, 10785 Berlin